Tesamorelin: A Peptide With a Drug Label

The approval that makes it unusual

FDA approved Egrifta on November 10, 2010 under application 022505. Theratechnologies sponsored the application, and the approved indication was reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. The approval belongs to that product, made within its defined manufacturing and regulatory system, for that specific indication.

The application then followed a rare second regulatory step. Effective March 23, 2020, application 022505 transitioned by operation of the Biologics Price Competition and Innovation Act from an approved new drug application to a licensed biologics license application. Tesamorelin is therefore regulated as a biologic. The substance did not change that morning, but the governing application framework did.

The product family kept developing inside the same application. FDA approved Egrifta WR, an 11.6 mg multi-dose vial formulation, on March 25, 2025. Fifteen years after the first approval, the file is still active.

What the pivotal trials measured

The approval record rests on a defined clinical program, not on the molecule's name alone. NCT00123253 was a 26-week randomised, placebo-controlled Phase 3 study in 412 participants sponsored by Theratechnologies. Results published in the New England Journal of Medicine in 2007 reported a reduction in visceral adipose tissue of about 15 percent relative to placebo.

A later study asked a different question. NCT01263717 enrolled roughly 50 participants in a randomised six-month trial and reported an effect on liver fat alongside visceral fat. Its results appeared in JAMA in 2014. That later finding is part of the research record, but it does not create another approved indication. Trial outcomes, label language, and future research questions remain separate layers of evidence.

Where research-chemical tesamorelin sits

A research vial can contain tesamorelin without becoming Egrifta. It does not inherit application 022505, the approved indication, or the controls documented for the branded biologic. Its relevant questions are instead identity, lot traceability, analytical results, stated intended use, and the documentation supplied by its own vendor.

FDA activity gives a concrete example of why the product context matters. A Form 483 issued to Revive Rx Pharmacy in Houston on February 7, 2025 listed "Tesamorelin 12 mg per Vial for Injection" among compounded products cited in observations concerning deficient aseptic media-fill practice. The document records observations at that facility. It is not necessary to turn it into a broader legal conclusion about every form of tesamorelin.

Tesamorelin also was not one of the substances named for review at the July 23 and 24, 2026 Pharmacy Compounding Advisory Committee meeting. The Federal Register notice listed BPC-157, KPV, TB-500, MOTS-c, emideltide, semax, and epitalon. That list establishes the meeting agenda, nothing more.

Sport rules are a separate framework. WADA's 2026 Prohibited List took effect January 1, 2026. Tesamorelin is a growth hormone releasing factor analogue, and that class falls under section S2, prohibited at all times. USADA announced a four-year period of ineligibility for triathlete Anthony McCauley, with tesamorelin among the substances involved. Researchers working around tested sport therefore have an additional status layer to document.

The same separation of contexts appears elsewhere in the catalogue. The profile of GHK-Cu as both a cosmetic ingredient and research chemical examines another molecule that crosses category boundaries, while the research-peptide company comparison framework focuses on the evidence attached to a vendor and lot.

Documentation for a research vial

For a research vial, documentation begins with the physical lot. The number on the vial should match the number on its report, as outlined in the guide to verifying a certificate of analysis against a specific lot. The named analyte and declared salt form should also align with the material described on the page.

Each analytical method then answers a different question. LC-MS supports identity, HPLC reports chromatographic purity, and endotoxin testing measures endotoxin burden. Curo's quality and testing standard consists of exactly those three methods. A purity percentage cannot substitute for an identity result, and neither one substitutes for a matching lot record.

This is the practical counterpart to the regulatory story. Egrifta's approval is documented through its own application and label. A research vial is documented through its own identity, lot, and analytical records. The molecule connects the two contexts, but the paperwork does not travel with the sequence.

Further reading

CJC-1295 is the other growth hormone releasing factor analogue in the catalogue, and it raises a different problem: the name covers two molecules, one of which binds albumin and persists far longer than the other. That comparison is drawn out in what the DAC modification changes about CJC-1295.

Ipamorelin offers a third variation on the same theme. It never reached approval, but unlike most research-catalogue peptides it did complete two Phase 2 trials and publish a clear result, which is covered in the ipamorelin trial record.

Two more peptides sit either side of that line. PT-141 reached approval as Vyleesi and carries a label whose limitations are more informative than its indication, covered in the PT-141 and bremelanotide profile. Thymosin alpha-1 went the other way, collecting four orphan drug designations without ever being approved, which is traced in the thymosin alpha-1 orphan drug record.

Common questions

Is tesamorelin FDA approved?

Egrifta, a specific tesamorelin product, was FDA approved in 2010 for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. That approval does not make every research vial an approved product.

Why is tesamorelin regulated as a biologic?

Application 022505 transitioned from an approved new drug application to a licensed biologics license application on March 23, 2020, by operation of the Biologics Price Competition and Innovation Act.

What did the pivotal Phase 3 trial measure?

The 26-week study compared tesamorelin with placebo in 412 participants and reported a change in visceral adipose tissue. The result was about a 15 percent reduction relative to placebo.

What should a tesamorelin research COA show?

It should connect the vial to a specific lot record, identify the analyte clearly, and present the relevant HPLC, LC-MS, and endotoxin results without blending their distinct meanings.